nach oben

Erschienen in:

01.02.2012 | Laboratory Investigation - Human/Animal Tissue

Downregulation of KIF23 suppresses glioma proliferation

verfasst von: Satoshi Takahashi, Noemi Fusaki, Shigeki Ohta, Yoshihiro Iwahori, Yukihiko Iizuka, Kohei Inagawa, Yutaka Kawakami, Kazunari Yoshida, Masahiro Toda

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

To identify therapeutic molecular targets for glioma, we performed modified serological identification of antigens by recombinant complementary DNA (cDNA) expression cloning using sera from a mouse glioma model. Two clones, kinesin family member 23 (Kif23) and structural maintenance of chromosomes 4 (Smc4), were identified as antigens through immunological reaction with sera from mice harboring synergic GL261 mouse glioma and intratumoral inoculation with a mutant herpes simplex virus. The human Kif23 homolog KIF23 is a nuclear protein that localizes to the interzone of mitotic spindles, acting as a plus-end-directed motor enzyme that moves antiparallel microtubules in vitro. Expression analysis revealed a higher level of KIF23 expression in glioma tissues than in normal brain tissue. The introduction of small interfering RNA (siRNA) targeting KIF23 into two different glioma cell lines, U87MG and SF126, downregulated KIF23 expression, which significantly suppressed glioma cell proliferation in vitro. KIF23 siRNA-treated glioma cells exhibited larger cell bodies with two or more nuclei compared with control cells. In vivo analysis using mouse xenograft showed that KIF23 siRNA/DNA chimera-treated tumors were significantly smaller than tumors treated with control siRNA/DNA chimera. Taken together, our results indicate that downregulation of KIF23 decreases proliferation of glioma cells and that KIF23 may be a novel therapeutic target in malignant glioma.

Prados MD, Levin V (2000) Biology and treatment of malignant glioma. Semin Oncol 27(3 Supplement 6):1–10

Takahashi S, Hirose Y, Ikeda E, Fukaya R, Kawase T (2007) Chromosome arm 1q gain associated with good response to chemotherapy in a malignant glioma case report. J Neurosurg 106(3):488–494. doi:10.3171/jns.2007.106.3.488 PubMedCrossRef

Takahashi S, Yamada-Okabe H, Hamada K, Ohta S, Kawase T, Yoshida K, Toda M (2010) Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells. J Neurooncol 103(2):267–276. doi:10.1007/s11060-010-0398-z PubMedCrossRef

Tabuse M, Ohta S, Ohashi Y, Fukaya R, Misawa A, Yoshida K, Kawase T, Saya H, Thirant C, Chneiweiss H, Matsuzaki Y, Okano H, Kawakami Y, Toda M (2011) Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol Cancer 10:60. doi:10.1186/1476-4598-10-60 PubMedCrossRef

Nislow C, Lombillo VA, Kuriyama R, McIntosh JR (1992) A plus-end-directed motor enzyme that moves antiparallel microtubules in vitro localizes to the interzone of mitotic spindles. Nature 359(6395):543–547. doi:10.1038/359543a0 PubMedCrossRef

Liu X, Zhou T, Kuriyama R, Erikson RL (2004) Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J Cell Sci 117(Pt 15):3233–3246. doi:10.1242/jcs.01173 PubMedCrossRef

Zhu C, Bossy-Wetzel E, Jiang W (2005) Recruitment of MKLP1 to the spindle midzone/midbody by INCENP is essential for midbody formation and completion of cytokinesis in human cells. Biochem J 389(Pt 2):373–381. doi:10.1042/BJ20050097 PubMed

Calligaris D, Verdier-Pinard P, Devred F, Villard C, Braguer D, Lafitte D (2010) Microtubule targeting agents: from biophysics to proteomics. Cell Mol Life Sci 67(7):1089–1104. doi:10.1007/s00018-009-0245-6 PubMedCrossRef

Vasiliev JM, Gelfand IM, Domnina LV, Ivanova OY, Komm SG, Olshevskaja LV (1970) Effect of colcemid on the locomotory behaviour of fibroblasts. J Embryol Exp Morphol 24(3):625–640PubMed

10.

Kline-Smith SL, Walczak CE (2004) Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. Mol Cell 15(3):317–327. doi:10.1016/j.molcel.2004.07.012 PubMedCrossRef

11.

Wittmann T, Hyman A, Desai A (2001) The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 3(1):E28–E34. doi:10.1038/35050669 PubMedCrossRef

12.

Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1(9):938–943PubMedCrossRef

13.

Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K (2008) Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 36(7):2136–2151. doi:10.1093/nar/gkn042 PubMedCrossRef

14.

National Cancer Institute (2005) REMBRANDT home page. http://rembrandt.nci.nih.gov. Accessed July 7, 2011

15.

Seguin L, Liot C, Mzali R, Harada R, Siret A, Nepveu A, Bertoglio J (2009) CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol Cell Biol 29(2):570–581. doi:10.1128/MCB.01275-08 PubMedCrossRef

16.

Li WM, Webb SE, Chan CM, Miller AL (2008) Multiple roles of the furrow deepening Ca2+ transient during cytokinesis in zebrafish embryos. Dev Biol 316(2):228–248. doi:10.1016/j.ydbio.2008.01.027 PubMedCrossRef

17.

Neef R, Klein UR, Kopajtich R, Barr FA (2006) Cooperation between mitotic kinesins controls the late stages of cytokinesis. Curr Biol 16(3):301–307. doi:10.1016/j.cub.2005.12.030 PubMedCrossRef

18.

Kuriyama R, Gustus C, Terada Y, Uetake Y, Matuliene J (2002) CHO1, a mammalian kinesin-like protein, interacts with F-actin and is involved in the terminal phase of cytokinesis. J Cell Biol 156(5):783–790. doi:10.1083/jcb.200109090 PubMedCrossRef

19.

Chen MC, Zhou Y, Detrich HW 3rd (2002) Zebrafish mitotic kinesin-like protein 1 (Mklp1) functions in embryonic cytokinesis. Physiol Genomics 8(1):51–66. doi:10.1152/physiolgenomics.00042.2001 PubMed

20.

Jain E, Bairoch A, Duvaud S, Phan I, Redaschi N, Suzek BE, Martin MJ, McGarvey P, Gasteiger E (2009) Infrastructure for the life sciences: design and implementation of the UniProt website. BMC Bioinformatics 10:136. doi:10.1186/1471-2105-10-136 PubMedCrossRef

21.

The UniProt Consortium (2011) Ongoing and future developments at the Universal Protein Resource. Nucleic Acids Res 39 (database issue):D214–219. doi:10.1093/nar/gkq1020

22.

Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 92(25):11810–11813PubMedCrossRef

23.

Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94(5):1914–1918PubMedCrossRef

24.

Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D (2010) Assessment of vaccine-induced CD4 T cell responses to the 119–143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers. Clin Cancer Res 16(18):4607–4615. doi:10.1158/1078-0432.CCR-10-1485 PubMedCrossRef

25.

Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jager D, Panicali D, Hoffman E, Pan L, Oettgen H, Old LJ, Knuth A (2006) Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103(39):14453–14458. doi:10.1073/pnas.0606512103 PubMedCrossRef

26.

Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O’Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104(21):8947–8952. doi:10.1073/pnas.0703395104 PubMedCrossRef

27.

Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M (2004) Identification of a human glioma antigen, SOX6, recognized by patients’ sera. Oncogene 23(7):1420–1427. doi:10.1038/sj.onc.1207252 PubMedCrossRef

28.

Iizuka Y, Kojima H, Kobata T, Kawase T, Kawakami Y, Toda M (2006) Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine. Int J Cancer 118(4):942–949. doi:10.1002/ijc.21432 PubMedCrossRef

29.

Boone CW, Paranjpe M, Orme T, Gillette R (1974) Virus-augmented tumor transplantation antigens: evidence for a helper antigen mechanism. Int J Cancer 13(4):543–551PubMedCrossRef

30.

Freedman RS, Bowen JM, Herson JH, Wharton JT, Edwards CL, Rutledge FN (1983) Immunotherapy for vulvar carcinoma with virus-modified homologous extracts. Obstet Gynecol 62(6):707–714PubMed

31.

Cassel WA, Murray DR, Phillips HS (1983) A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 52(5):856–860PubMedCrossRef

32.

Kobayashi H, Gotohda E, Hosokawa M, Kodama T (1975) Inhibition of metastasis in rats immunized with xenogenized autologous tumor cells after excision of the primary tumor. J Natl Cancer Inst 54(4):997–999PubMed

33.

Toda M, Martuza RL, Kojima H, Rabkin SD (1998) In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160(9):4457–4464PubMed

34.

Toda M, Rabkin SD, Kojima H, Martuza RL (1999) Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10(3):385–393. doi:10.1089/10430349950018832 PubMedCrossRef

35.

Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y (2002) Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther 9(4):356–364. doi:10.1038/sj.cgt.7700446 PubMedCrossRef

36.

Endo T, Toda M, Watanabe M, Iizuka Y, Kubota T, Kitajima M, Kawakami Y (2002) In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer. Cancer Gene Ther 9(2):142–148. doi:10.1038/sj.cgt.7700407 PubMedCrossRef

37.

Iizuka Y, Suzuki A, Kawakami Y, Toda M (2004) Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12. J Immunother 27(2):92–98PubMedCrossRef

38.

Ausman JI, Shapiro WR, Rall DP (1970) Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 30(9):2394–2400PubMed

39.

O I Blaszczyk-Thurin M, Shen CT, Ertl HC (2003) A DNA vaccine expressing tyrosinase-related protein-2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther 10(9):678–688. doi:10.1038/sj.cgt.7700620 CrossRef

40.

Plautz GE, Touhalisky JE, Shu S (1997) Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 178(2):101–107. doi:10.1006/cimm.1997.1140 PubMedCrossRef

41.

Aoki H, Mizuno M, Natsume A, Tsugawa T, Tsujimura K, Takahashi T, Yoshida J (2001) Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 50(9):463–468PubMedCrossRef

42.

Liu X, Erikson RL (2007) The nuclear localization signal of mitotic kinesin-like protein Mklp-1: effect on Mklp-1 function during cytokinesis. Biochem Biophys Res Commun 353(4):960–964. doi:10.1016/j.bbrc.2006.12.142 PubMedCrossRef

43.

Rowinsky EK, Calvo E (2006) Novel agents that target tublin and related elements. Semin Oncol 33(4):421–435. doi:10.1053/j.seminoncol.2006.04.006 PubMedCrossRef

44.

Parness J, Horwitz SB (1981) Taxol binds to polymerized tubulin in vitro. J Cell Biol 91(2 Pt 1):479–487

45.

Derry WB, Wilson L, Jordan MA (1995) Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry 34(7):2203–2211PubMedCrossRef

46.

Dhamodharan R, Jordan MA, Thrower D, Wilson L, Wadsworth P (1995) Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol Cell 6(9):1215–1229PubMed

47.

Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84(1):265–269PubMedCrossRef

48.

Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roder N, Loffler K, Lange C, Fechtner M, Mopert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68(23):9788–9798. doi:10.1158/0008-5472.can-08-2428 PubMedCrossRef

49.

Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A (2006) 3’ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3(3):199–204. doi:10.1038/nmeth854 PubMedCrossRef

50.

Judge AD, Bola G, Lee AC, MacLachlan I (2006) Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13(3):494–505. doi:10.1016/j.ymthe.2005.11.002 PubMedCrossRef

51.

Ueyama K, Ikeda K, Sato W, Nakasato N, Horie-Inoue K, Takeda S, Inoue S (2010) Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth. Cancer Gene Ther 17(9):624–632. doi:10.1038/cgt.2010.19 PubMedCrossRef

52.

Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T (2005) Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 115(4):978–985. doi:10.1172/jci23043 PubMed

Titel: Downregulation of KIF23 suppresses glioma proliferation
verfasst von: Satoshi Takahashi
Noemi Fusaki
Shigeki Ohta
Yoshihiro Iwahori
Yukihiko Iizuka
Kohei Inagawa
Yutaka Kawakami
Kazunari Yoshida
Masahiro Toda
Publikationsdatum: 01.02.2012
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2012
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-011-0706-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Erratum to: Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life

Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma

A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas

Dosimetric comparison of Linac-based (BrainLAB®) and robotic radiosurgery (CyberKnife®) stereotactic system plans for acoustic schwannoma

Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology